Securities Litigation
Page 1 • 2 itemsTrack global pharma securities litigation trends. Stay ahead of regulatory scrutiny, investor lawsuits, and market impact with NovaPharmaNews intelligence.
ImmunityBio (IBRX) Faces FDA Warning Letter and Class Action Lawsuit Over Ankt Drug Promotion Violations
ImmunityBio faces securities lawsuit after FDA warning letter over promotional claims for lead biologic Ankt, impacting IBRX stock from January-March 2026.
ImmunityBio (IBRX) Faces Securities Lawsuit After FDA Warning Letter Over Cancer Treatment Claims
ImmunityBio stock plunges 21% as company faces class action lawsuit following FDA warning letter about misleading cancer treatment claims by executives.